SG11201408459VA - Purification of virus like particles - Google Patents
Purification of virus like particlesInfo
- Publication number
- SG11201408459VA SG11201408459VA SG11201408459VA SG11201408459VA SG11201408459VA SG 11201408459V A SG11201408459V A SG 11201408459VA SG 11201408459V A SG11201408459V A SG 11201408459VA SG 11201408459V A SG11201408459V A SG 11201408459VA SG 11201408459V A SG11201408459V A SG 11201408459VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- montana
- particles
- virus
- bozeman
- Prior art date
Links
- 239000002245 particle Substances 0.000 title abstract 3
- 241000700605 Viruses Species 0.000 title abstract 2
- 238000000746 purification Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 239000000356 contaminant Substances 0.000 abstract 1
- 239000003599 detergent Substances 0.000 abstract 1
- 238000003306 harvesting Methods 0.000 abstract 1
- 230000002779 inactivation Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16051—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Analytical Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261663218P | 2012-06-22 | 2012-06-22 | |
| US201361794086P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/047249 WO2013192604A1 (en) | 2012-06-22 | 2013-06-24 | Purification of virus like particles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408459VA true SG11201408459VA (en) | 2015-01-29 |
Family
ID=49769461
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408459VA SG11201408459VA (en) | 2012-06-22 | 2013-06-24 | Purification of virus like particles |
| SG10201610753YA SG10201610753YA (en) | 2012-06-22 | 2013-06-24 | Purification of virus like particles |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201610753YA SG10201610753YA (en) | 2012-06-22 | 2013-06-24 | Purification of virus like particles |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10167320B2 (enExample) |
| EP (1) | EP2864478B1 (enExample) |
| JP (1) | JP6553509B2 (enExample) |
| KR (1) | KR102110876B1 (enExample) |
| CN (2) | CN114085273B (enExample) |
| AR (1) | AR091538A1 (enExample) |
| AU (1) | AU2013277959B2 (enExample) |
| CA (1) | CA2879815A1 (enExample) |
| IN (1) | IN2015DN00089A (enExample) |
| JO (1) | JOP20130186B1 (enExample) |
| MX (1) | MX366234B (enExample) |
| SG (2) | SG11201408459VA (enExample) |
| TW (1) | TWI647310B (enExample) |
| UY (1) | UY34875A (enExample) |
| WO (1) | WO2013192604A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2618885T3 (es) | 2006-09-29 | 2017-06-22 | Takeda Vaccines, Inc. | Formulaciones de vacuna para norovirus |
| KR20170001720A (ko) | 2007-03-14 | 2017-01-04 | 다케다 백신즈 인코포레이티드 | 바이러스 유사 입자 정제 |
| KR20100083150A (ko) | 2007-09-18 | 2010-07-21 | 리고사이트 파머슈티컬즈 인코퍼레이티드 | 노로바이러스에 대한 보호면역반응을 제공하는 방법 |
| HK1199202A1 (en) | 2011-07-11 | 2015-06-26 | 武田疫苗股份有限公司 | Parenteral norovirus vaccine formulations |
| JOP20130186B1 (ar) | 2012-06-22 | 2021-08-17 | Takeda Vaccines Montana Inc | تنقية الجزيئات الشبيهة بالفيروسات |
| EP3020808B1 (en) * | 2013-07-11 | 2019-09-11 | Takara Bio Inc. | Method for manufacturing adeno-associated virus |
| KR102474663B1 (ko) | 2013-10-03 | 2022-12-07 | 다케다 백신즈 인코포레이티드 | 세포주로부터 랍도바이러스를 탐지 및 제거하는 방법 |
| CN103981084B (zh) * | 2014-05-29 | 2015-11-18 | 黑龙江省科学院微生物研究所 | 水中病毒分离提取装置及水中札幌病毒的提取方法 |
| JP6616329B2 (ja) * | 2015-01-09 | 2019-12-04 | タカラバイオ株式会社 | 非エンベロープウイルス粒子の製造方法 |
| EP3245306A4 (en) | 2015-01-16 | 2018-09-05 | Takeda Vaccines, Inc. | Detection of particle-contained reverse transcriptase activity |
| CN105907729B (zh) * | 2015-05-05 | 2019-08-16 | 广东东阳光药业有限公司 | 一种制备人乳头瘤病毒l1蛋白类病毒样颗粒的方法 |
| CN107034198B (zh) * | 2015-07-15 | 2021-03-09 | 长春百克生物科技股份公司 | 一种嵌合诺如病毒p颗粒及其制备和应用 |
| WO2017040265A1 (en) | 2015-08-28 | 2017-03-09 | Nanotherapeutics, Inc. | Norovirus vaccine |
| CN105779399A (zh) * | 2016-03-28 | 2016-07-20 | 广西壮族自治区林业科学研究院 | 一种昆虫杆状病毒纯化方法 |
| GB201614050D0 (en) | 2016-08-17 | 2016-09-28 | Glaxosmithkline Ip Dev Ltd | Method for purifying viral vectors |
| CN109689092A (zh) * | 2016-09-01 | 2019-04-26 | 武田疫苗股份有限公司 | 用于产生用于疫苗生产的病毒的方法 |
| EP3420076B1 (en) | 2017-03-06 | 2024-02-21 | Guangzhou Realbenefitspot Pharmaceutical Co., Ltd. | Methods of producing and characterizing virus vaccine and virus vaccine composition |
| EP4382183A3 (en) | 2017-03-06 | 2024-08-21 | Guangzhou Realbenefitspot Pharmaceutical Co., Ltd. | Methods of producing and characterizing virus vaccine and virus vaccine composition |
| EP3752185A1 (en) | 2018-02-15 | 2020-12-23 | Icon Genetics GmbH | Immunogenic composition and vaccine for generating an immune response to norovirus |
| CN108676781A (zh) * | 2018-05-18 | 2018-10-19 | 山东信得动物疫苗有限公司 | 一种重组禽流感病毒的工业化纯化方法 |
| CN108776225A (zh) * | 2018-05-23 | 2018-11-09 | 中国农业科学院兰州兽医研究所 | 猪细小病毒VLPs抗体检测试剂盒及其制备方法、应用 |
| ES2953232T3 (es) | 2019-03-12 | 2023-11-08 | Icon Genetics Gmbh | Partículas similares a norovirus con estabilidad mejorada |
| CN115279896A (zh) | 2019-09-30 | 2022-11-01 | 比奥维拉迪维治疗股份有限公司 | 慢病毒载体配制品 |
| WO2022246323A1 (en) | 2021-05-21 | 2022-11-24 | Takeda Vaccines, Inc. | Solid composition, freeze-drying method and glass vial |
| JP2024524360A (ja) * | 2021-06-28 | 2024-07-05 | ブイエスティー エルエルシー ディービーエー メジン ラボ | サポウイルスワクチン |
| CN116789773B (zh) * | 2022-11-30 | 2024-02-20 | 华北制药金坦生物技术股份有限公司 | 一种胞内表达病毒样颗粒的粗纯方法 |
| WO2025077800A1 (en) * | 2023-10-12 | 2025-04-17 | Chengdu Kanghua Biological Products Co., Ltd. | Purification of norovirus virus-like particles (vlps) |
| CN118126202B (zh) * | 2024-05-07 | 2024-07-30 | 上海瑞宙生物科技有限公司 | 一种诺如病毒类病毒颗粒及其应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2833106B2 (ja) | 1990-02-21 | 1998-12-09 | 株式会社島津製作所 | 液体クロマトグラフ |
| WO1994026087A2 (en) | 1993-05-14 | 1994-11-24 | Connor Kim C O | Recombinant protein production and insect cell culture and process |
| BR9507657A (pt) | 1994-05-16 | 1997-09-09 | Merck & Co Inc | Proteina isolada e purificada de papilomavirus recombinante capsideos particulas semelhantes a virus processos a virus processos para produzir a proteina para tratar ou prevenir a infecçao por papilomavirus para produzir uma proteina de capsideo de papilomavirus recombinante montada em um capsideo ou particula semelhante a virus e para induzir uma resposta imune em um animal vertebrado composiçoes farmacêuticas kit para a detecçao de papilomavirus ou anticorpos para papilomavirus e sistema sinte |
| AR004464A1 (es) | 1994-11-14 | 1998-12-16 | Merck Sharp & Dohme | Un metodo para producir una proteina de capside de papilomavirus |
| JP3316325B2 (ja) * | 1994-12-20 | 2002-08-19 | 富士シリシア化学株式会社 | ビール安定化処理用シリカゲル及びその製造方法並びにビールの安定化処理方法 |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| JP4021493B2 (ja) | 1996-11-08 | 2007-12-12 | ザ ガヴァメント オブ ザ ユナイテッド ステイツ オブ アメリカ、レプリゼンテッド バイ ザ セクレタリー、 デパートメント オブ ヘルス アンド ヒューマン サーヴィスィズ | Ｃ型肝炎ウイルス様粒子の合成および精製 |
| DE69835294T2 (de) | 1997-09-05 | 2007-07-26 | Medimmune, Inc. | Methode zur in vitro auseinander- und wiederzusammensetzung von papillomavirus virusähnlichen teilchen (vlps) |
| DE19823814A1 (de) | 1998-05-27 | 1999-12-02 | Octapharma Ag Ziegelbruecke | Verfahren zur Trennung und/oder Isolierung von Plasmaproteinen mit annularer Chromatographie |
| PL347472A1 (en) | 1998-08-14 | 2002-04-08 | Merck & Co Inc | Process for purifying human papillomavirus virus-like particles |
| PT1150712E (pt) * | 1999-02-05 | 2008-12-22 | Merck & Co Inc | Formulações para a vacina do vírus do papiloma humano |
| US6349843B1 (en) | 1999-04-01 | 2002-02-26 | The Vollrath Company Llc | Pan removal ramp |
| EP1186890B1 (en) | 1999-06-22 | 2013-01-02 | Japan as Represented by Director-General of National Institute of Infectious Diseases | Srsv detection kit |
| DE10012732A1 (de) | 2000-03-18 | 2001-09-20 | Aventis Behring Gmbh | Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung |
| JP2003066021A (ja) | 2001-08-28 | 2003-03-05 | Hiroshi Shionoya | 連続分取液体クロマトグラフィー装置とそれを用いる方法 |
| WO2003068163A2 (en) | 2002-02-14 | 2003-08-21 | Novavax, Inc. | Optimization of gene sequences of chimeric virus-like particles for expression in insect cells |
| JP4319979B2 (ja) | 2002-04-26 | 2009-08-26 | ジェネンテック・インコーポレーテッド | タンパク質の非アフィニティ精製 |
| WO2004020971A2 (en) | 2002-08-28 | 2004-03-11 | Introgen Therapeutics Inc. | Chromatographic methods for adenovirus purification |
| US7879338B2 (en) | 2003-07-21 | 2011-02-01 | Boyce Thompson Institute For Plant Research | Vectors and methods for immunization against norovirus using transgenic plants |
| US7481997B1 (en) | 2004-02-12 | 2009-01-27 | Montana State University | Snow mountain virus genome sequence, virus-like particles and methods of use |
| WO2006138514A2 (en) | 2005-06-16 | 2006-12-28 | Children's Hospital Medical Center | Novel norovirus particle for use as an antiviral or vaccine |
| EP1736538A1 (en) | 2005-06-21 | 2006-12-27 | Cytos Biotechnology AG | Process for the preparative purification of virus-like-particles (VLPs) |
| WO2007081447A2 (en) | 2005-11-22 | 2007-07-19 | Novartis Vaccines And Diagnostics, Inc. | Norovirus and sapovirus antigens |
| EP3320919B1 (en) | 2005-12-29 | 2020-05-27 | Boehringer Ingelheim Animal Health USA Inc. | Multivalent pcv2 immunogenic compositions and methods of producing such compositions |
| WO2008094197A2 (en) | 2006-07-27 | 2008-08-07 | Ligocyte Pharmaceuticals, Inc. | Chimeric influenza virus-like particles |
| ES2618885T3 (es) * | 2006-09-29 | 2017-06-22 | Takeda Vaccines, Inc. | Formulaciones de vacuna para norovirus |
| US8202967B2 (en) | 2006-10-27 | 2012-06-19 | Boehringer Ingelheim Vetmedica, Inc. | H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use |
| KR20170001720A (ko) * | 2007-03-14 | 2017-01-04 | 다케다 백신즈 인코포레이티드 | 바이러스 유사 입자 정제 |
| EP2027875A1 (en) * | 2007-08-23 | 2009-02-25 | Octapharma AG | A Process for Isolation and Purification of a Target Protein free of Prion Protein (PrPSC) |
| KR20100083150A (ko) | 2007-09-18 | 2010-07-21 | 리고사이트 파머슈티컬즈 인코퍼레이티드 | 노로바이러스에 대한 보호면역반응을 제공하는 방법 |
| EP2235165A1 (en) | 2007-12-21 | 2010-10-06 | Cytos Biotechnology AG | Process for clarifying cell homogenates |
| AU2009279456B2 (en) | 2008-08-08 | 2015-02-05 | Takeda Vaccines, Inc. | Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity |
| CA2742295A1 (en) | 2008-11-03 | 2010-06-03 | Ligocyte Pharmaceuticals, Inc. | Improved methods for isolating enveloped virus-based vlps free of infectious agents |
| US8945895B2 (en) * | 2009-07-31 | 2015-02-03 | Baxter International Inc. | Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof |
| CA2787666A1 (en) | 2010-01-21 | 2011-07-28 | Ligocyte Pharmaceuticals, Inc. | Targeted heterologous antigen presentation on calicivirus virus-like particles |
| CA2812058C (en) * | 2010-09-20 | 2019-04-16 | Bio-Rad Laboratories, Inc. | Dissociation of product-complexed contaminants in chromatography |
| FI122520B (fi) | 2010-10-15 | 2012-03-15 | Vesna Blazevic | Noroviruksen kapsidi ja rotaviruksen VP6-proteiini käytettäväksi yhdistelmärokotteena |
| CN102260651A (zh) | 2011-06-24 | 2011-11-30 | 华中科技大学同济医学院附属协和医院 | 一种纯化病毒样颗粒蛋白的方法及其应用 |
| JOP20130186B1 (ar) | 2012-06-22 | 2021-08-17 | Takeda Vaccines Montana Inc | تنقية الجزيئات الشبيهة بالفيروسات |
| JP2015015931A (ja) | 2013-07-12 | 2015-01-29 | 株式会社Ｕｍｎファーマ | ウイルス様粒子を含む培養物の製造方法 |
-
2013
- 2013-06-19 JO JOP/2013/0186A patent/JOP20130186B1/ar active
- 2013-06-21 TW TW102122276A patent/TWI647310B/zh active
- 2013-06-24 SG SG11201408459VA patent/SG11201408459VA/en unknown
- 2013-06-24 CA CA2879815A patent/CA2879815A1/en active Pending
- 2013-06-24 EP EP13807804.3A patent/EP2864478B1/en active Active
- 2013-06-24 SG SG10201610753YA patent/SG10201610753YA/en unknown
- 2013-06-24 UY UY0001034875A patent/UY34875A/es active IP Right Grant
- 2013-06-24 CN CN202111173161.7A patent/CN114085273B/zh active Active
- 2013-06-24 AU AU2013277959A patent/AU2013277959B2/en active Active
- 2013-06-24 US US13/925,449 patent/US10167320B2/en active Active
- 2013-06-24 WO PCT/US2013/047249 patent/WO2013192604A1/en not_active Ceased
- 2013-06-24 MX MX2014015842A patent/MX366234B/es active IP Right Grant
- 2013-06-24 KR KR1020157001131A patent/KR102110876B1/ko active Active
- 2013-06-24 JP JP2015518633A patent/JP6553509B2/ja active Active
- 2013-06-24 AR ARP130102218 patent/AR091538A1/es active IP Right Grant
- 2013-06-24 CN CN201380043618.XA patent/CN104583393A/zh active Pending
-
2015
- 2015-01-06 IN IN89DEN2015 patent/IN2015DN00089A/en unknown
-
2018
- 2018-11-27 US US16/201,073 patent/US11091519B2/en active Active
-
2021
- 2021-08-11 US US17/399,731 patent/US12286456B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AR091538A1 (es) | 2015-02-11 |
| CN114085273B (zh) | 2024-07-12 |
| HK1210210A1 (en) | 2016-04-15 |
| AU2013277959A1 (en) | 2015-01-22 |
| US20220213147A1 (en) | 2022-07-07 |
| US10167320B2 (en) | 2019-01-01 |
| CA2879815A1 (en) | 2013-12-27 |
| KR20150051988A (ko) | 2015-05-13 |
| IN2015DN00089A (enExample) | 2015-05-29 |
| KR102110876B1 (ko) | 2020-05-14 |
| UY34875A (es) | 2013-12-31 |
| EP2864478A1 (en) | 2015-04-29 |
| JP6553509B2 (ja) | 2019-07-31 |
| US20190169236A1 (en) | 2019-06-06 |
| WO2013192604A1 (en) | 2013-12-27 |
| CN114085273A (zh) | 2022-02-25 |
| JP2015521628A (ja) | 2015-07-30 |
| MX2014015842A (es) | 2015-09-07 |
| JOP20130186B1 (ar) | 2021-08-17 |
| US12286456B2 (en) | 2025-04-29 |
| US20140004145A1 (en) | 2014-01-02 |
| EP2864478B1 (en) | 2020-12-09 |
| MX366234B (es) | 2019-07-03 |
| SG10201610753YA (en) | 2017-02-27 |
| TWI647310B (zh) | 2019-01-11 |
| AU2013277959B2 (en) | 2019-05-16 |
| EP2864478A4 (en) | 2015-12-02 |
| TW201406956A (zh) | 2014-02-16 |
| CN104583393A (zh) | 2015-04-29 |
| US11091519B2 (en) | 2021-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201408459VA (en) | Purification of virus like particles | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201808592PA (en) | Method for selection of high m6p recombinant proteins | |
| SG11201810048VA (en) | Tri-segmented pichinde viruses as vaccine vectors | |
| SG11201903042VA (en) | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201806340YA (en) | Zika virus vaccine | |
| SG11201903514VA (en) | Novel cd47 monoclonal antibodies and uses thereof | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201807913XA (en) | Stabilized soluble pre-fusion rsv f proteins | |
| SG11201804411TA (en) | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201808709VA (en) | T cell receptors | |
| SG11201906431UA (en) | Method for the treatment of thromboembolism | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201811363YA (en) | Anti-zika virus antibodies and methods of use | |
| SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201408153YA (en) | Prostate-specific membrane antigen antibody drug conjugates | |
| SG11201804255QA (en) | Treatment of intrahepatic cholestasis and related liver diseases | |
| SG11201810078PA (en) | Stabilized pre-fusion rsv f proteins | |
| SG11201811446SA (en) | Process for recovering viral products using functionalised chromatography media | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201900027XA (en) | Anti-o2 antibodies and uses thereof |